Robert A. Anderson - Aug 31, 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Director
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Robert Anderson
Stock symbol
BIAF
Transactions as of
Aug 31, 2022
Transactions value $
$0
Form type
4
Date filed
12/2/2022, 08:31 PM
Previous filing
Dec 2, 2022
Next filing
Jul 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock, par value $0.007 Purchase +4.08K 4.08K Aug 31, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIAF Warrants (right to buy) Purchase +4.08K 4.08K Aug 31, 2022 Common Stock 4.08K $7.35 Direct F1, F2
transaction BIAF Non-tradeable Warrants (right to buy) Purchase +4.08K 4.08K Aug 31, 2022 Common Stock 4.08K $7.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2 The reported securities are included within 4,081 Units purchased by Mr. Anderson for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

Remarks:

Exhibit 24.1: Power of Attorney (Robert Anderson)